![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
NM Munoz, AJ Vita, SP Neeley, K McAllister, SM Spaethe, SR White and AR Leff
Department of Medicine, University of Chicago, Illinois.
The inhibitory effect of beta-2 adrenergic receptor stimulation on leukotriene C4 (LTC4) secretion and eosinophil peroxidase (EPO) release caused by exogenous activation with 10(-8) to 10(-6) M formyl-met-leu- phe (fMLP) + 5 micrograms/ml of cytochalasin B (Cyto B) in purified human peripheral blood eosinophils was studied. Cells from normal subjects were isolated by negative immunoselection and remained > or = 98% viable as determined by trypan blue exclusion. Duplicate aliquots of eosinophils (10(5) cells/intervention) were activated with 1) fMLP + Cyto B alone, 2) fMLP + Cyto B after pretreatment with 10(-8) M albuterol, 3) 10(-8) M albuterol + fMLP + Cyto B after pretreatment with 10(-8) M propranolol or 4) vehicle control. After incubation, the supernatants were tested for concentration of LTC4 and EPO. Concentration-related release of EPO was demonstrated for 10(-8) M fMLP + 5 micrograms/ml of Cyto B to 10(-6) M fMLP + 5 micrograms/ml of Cyto B, and the greatest concentration of fMLP was used in all subsequent studies. FMLP + Cyto B caused substantial LTC4 secretion in eosinophils (300 +/- 83.0 pg/ml) as compared to sham-activated eosinophils (3.3 +/- 1.9 pg/ml; P < .02). Similarly, maximum EPO release increased from 277 +/- 17.8 to 3956 +/- 1230 ng/10(6) cells (P < .02) after activation with fMLP + Cyto B. Treatment with albuterol decreased markedly both LTC4 secretion to 144 +/- 54.0 pg/ml (P < .05 vs. fMLP + Cyto B- activated eosinophils) and EPO release to 1993 +/- 368 ng/10(6) cells (P < .05 vs. fMLP + Cyto B-activated eosinophils).(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  P A Beckett and P H Howarth Pharmacotherapy and airway remodelling in asthma? Thorax, February 1, 2003; 58(2): 163 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. SPOELSTRA, H. F. KAUFFMAN, H. HOVENGA, J. A. NOORDHOEK, J. G. R. de MONCHY, and D. S. POSTMA Effects of Budesonide and Formoterol on Eosinophil Activation Induced by Human Lung Fibroblasts Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1229 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Munoz, G. A. van Seventer, R. T. Semnani, and A. R. Leff Augmentation of LTC4 synthesis in human eosinophils caused by CD3-stimulated Th2-like cells in vitro Am J Physiol Lung Cell Mol Physiol, June 1, 2000; 278(6): L1172 - L1179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. BOUSQUET, P. K. JEFFERY, W. W. BUSSE, M. JOHNSON, and A. M. VIGNOLA Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1720 - 1745. [Full Text]
|
|
|
|
|
|
N. M. Munoz, K. J. Hamann, K. F. Rabe, H. Sano, X. Zhu, and A. R. Leff Augmentation of eosinophil degranulation and LTC4 secretion by integrin-mediated endothelial cell adhesion Am J Physiol Lung Cell Mol Physiol, October 1, 1999; 277(4): L802 - L810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. SANO, N. M. MUÑOZ, H. SANO, J. CHOI, X. ZHU, B. JACOBS, and A. R. LEFF Inhibition of cPLA2 Translocation and Leukotriene C4 Secretion by Fluticasone Propionate in Exogenously Activated Human Eosinophils Am. J. Respir. Crit. Care Med., June 1, 1999; 159(6): 1903 - 1909. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Giembycz and M. A. Lindsay Pharmacology of the Eosinophil Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. I. Ezeamuzie and M. Al-Hage Differential Effects of Salbutamol and Salmeterol on Human Eosinophil Responses J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 25 - 31. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
